Hikma Pharmaceuticals Stock
Hikma Pharmaceuticals Stock
A loss of -1.410% shows a downward development for Hikma Pharmaceuticals.
Pros and Cons of Hikma Pharmaceuticals in the next few years
Pros
?
M***** P*******
?
W********* I********* f** t** n*** y****
?
B****
Cons
?
S********** s********
?
C******** o* t** e**********
?
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Hikma Pharmaceuticals vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Hikma Pharmaceuticals | -1.410% | 2.174% | -21.667% | -43.145% | -19.886% | -28.061% | -44.488% |
| Viatris Inc. | -1.450% | -4.271% | -9.917% | 40.596% | 13.811% | 27.472% | -0.909% |
| Repligen Corp. | -4.690% | -8.221% | -11.588% | -26.103% | -29.854% | -36.748% | -39.331% |
| Opko Health Inc. | 0.520% | 2.985% | -3.331% | -37.383% | -9.503% | -10.796% | -72.514% |
Comments
Hikma Pharmaceuticals (OTCMKTS:HKMPF) was downgraded by analysts at Barclays PLC to an "underweight" rating.
Show more
Ratings data for HKMPF provided by MarketBeat
Hikma Pharmaceuticals PLC (OTCMKTS: HKMPF) is now covered by analysts at BNP Paribas. They set an "outperform" rating on the stock.
Show more
Ratings data for HKMPF provided by MarketBeat